Reversible Myelofibrosis in Pediatric Renal Osteodystrophy

Sabulski, Anthony; Hughley, Erica; Nehus, Edward; Grier, David D.; Niss, Omar

doi:10.1016/j.jpeds.2020.07.051

Cited by 1 publication

(1 citation statement)

References 7 publications

(5 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Myelofibrosis resulting from secondary HPT caused by ESRD is an uncommon disease in young individuals (aged < 20 years old), and only few cases have been reported ( Table 1 ) ( 12 – 14 ). Treatment of HPT in renal disease consists of dietary modification, phosphate binders, and active vitamin D ( 7 ).…”

Section: Discussionmentioning

confidence: 99%

Case Report: Effects of Secondary Hyperparathyroidism Treatment on Improvement of Juvenile Nephronophthisis-Induced Pancytopenia and Myelofibrosis

et al. 2021

View full text Add to dashboard Cite

Secondary hyperparathyroidism (HPT) is a common complication of end-stage renal disease (ESRD) and may be an important precipitating factor for the development of myelofibrosis. However, there have been only a few reports on myelofibrosis caused by secondary HPT in children. We describe a case of a 15-year-old boy with myelofibrosis due to secondary HPT who was successfully treated with hemodialysis, erythropoietin, phosphate binders, and activated vitamin D agents. The patient had no past medical history and had been admitted to the hospital for abdominal pain. Routine blood examination revealed pancytopenia combined with renal impairment. Hyperphosphatemia, decreased 1,25-dehydroxyvitamin D, decreased serum calcium, and increased parathyroid hormone (PTH) levels were observed. Bone marrow biopsy confirmed myelofibrosis and renal biopsy revealed nephronophthisis (NPHP). The possibility of renal osteodystrophy and myelofibrosis due to secondary HPT was considered. Hemodialysis and erythropoietin were initiated and combined therapy with a phosphate binder and an active vitamin D agent achieved greater reduction of PTH levels, along with improvement of pancytopenia. As medical treatment for secondary HPT can lead to a reversal of myelofibrosis and avoid parathyroidectomy in children, prompt recognition of this condition has major implications for treatment. Therefore, despite its rarity, pediatricians should consider myelofibrosis due to secondary HPT as a cause of pancytopenia in patients with chronic kidney disease.

show abstract

Section: Discussionmentioning

confidence: 99%